Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Kenichi WatanabeNaoki NiikuraYuichiro KikawaMari ObaKokoro KobayashiHiroshi TadaShinji OzakiUhi TohYutaka YamamotoMichiko TsuneizumiToshitaka OkunoNobutaka IwakumaTakashi TakeshitaTakayuki IwamotoHiroshi IshiguroNorikazu MasudaShigehira SajiPublished in: Breast cancer research and treatment (2023)
Our findings suggest that palbociclib plus fulvestrant after disease progression despite fulvestrant monotherapy is potentially safe and effective in patients with HR-positive/HER2-negative advanced MBC.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- combination therapy
- open label
- squamous cell carcinoma
- study protocol
- clinical trial
- small cell lung cancer
- induced pluripotent stem cells
- randomized controlled trial
- phase iii
- current status
- breast cancer risk
- childhood cancer